2018
Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105).
Gounder M, Mahoney M, Van Tine B, Ravi V, Attia S, Deshpande H, Gupta A, Milhem M, Conry R, Movva S, Pishvaian M, Crawford J, Sabagh T, Maki R, Tap W, Lefkowitz R, Agaram N, Wright J, Dueck A, Schwartz G. Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105). Journal Of Clinical Oncology 2018, 36: 11500-11500. DOI: 10.1200/jco.2018.36.15_suppl.11500.Peer-Reviewed Original Research
2014
Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial.
Bastholt L, Brose M, Jarzab B, Schlumberger M, Siena S, De La Fouchardiere C, Paschke R, Deshpande H, Shi Y, Elisei R, Gao M, Li L, Prins K, Walker H, Mitchell D, Lettieri J, Molnar I, Kappeler C, Pena C. Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial. Journal Of Clinical Oncology 2014, 32: 6061-6061. DOI: 10.1200/jco.2014.32.15_suppl.6061.Peer-Reviewed Original Research